Arbutus Biopharma Corporation ABUS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's retained earnings?
- Arbutus Biopharma Corporation (ABUS) reported retained earnings of -$1.21B in Q1 2026.
- How has Arbutus Biopharma Corporation's retained earnings changed year-over-year?
- Arbutus Biopharma Corporation's retained earnings increased by 11.7% year-over-year, from -$1.37B to -$1.21B.
- What is the long-term trend for Arbutus Biopharma Corporation's retained earnings?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's retained earnings has grown at a 5.7% compound annual growth rate (CAGR), from -$1.05B to -$1.38B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.